Recent

% | $
Quotes you view appear here for quick access.

OneBeacon Insurance Group, Ltd. Message Board

snogreen 290 posts  |  Last Activity: Jul 11, 2016 1:05 PM Member since: Aug 30, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Seeing that Maxim got paid to do the placement with Sabby.....and Maxim also received 250,000 free warrants....I wonder if MAXM will write up and recommend RGRX? I had thought that the "quiet period" for write-ups & recos was about a month....turns out it is far shorter.....like, MAXM would be able to recommend RGRX this week if they wanted to:

    From SEC site...:

    "NYSE and FINRA rules now prohibit analysts from offering a favorable research rating or specific price target to induce investment banking business from companies. The rule changes also impose "quiet periods" that bar a firm that is acting as manager or co-manager of a securities offering from issuing a report on a company within 40 days after an initial public offering or within 10 days after a secondary offering for an inactively traded company."

    TEN days is the quiet period for RGRX:

    ""quiet periods" that bar a firm that is acting as manager or co-manager of a securities offering from issuing a report on a company........ within 10 days after a secondary offering for an inactively traded company."

    RGRX reported the deal JULY 1.today is JULY 11...ten days ago.. In theory, MAXM is free and clear tomorrow if they want.

  • Reply to

    bid .38 and ask .445 frozen assets

    by thebasiles777 Jul 11, 2016 11:11 AM
    snogreen snogreen Jul 11, 2016 12:01 PM Flag

    It seems pretty obvious.onvce the MM saw two things.....the supposed (yet again flopped trial (or muddy)......and money boke RGRX did what they(we) expected....another round of large dilution. That got us back to the mid to high 30 cent area....as they bet that it would. However, at this price the MM does not want to SHORT RGRX.....but neither do they want to OWN rgrx either.because they always have believed TB 4 is a POS. So if they won't short here and don't wish to buy.....you get a six cent spread. I don't mid the spread....long timers here play till the end game....all or none. I'd like to buy more, but Finkel always prevents me from.......I want to see detailed trial results....I want to see OSDI....I want to see glaucoma measures they did....I want to see Lee's trial start....I want o se WHEN they will start finla phase 3...I want to see that phase 3 design.. All this we need to see is in a "void".Finkel pretty much knows.and he is silent.

  • Reply to

    bid .38 and ask .445 frozen assets

    by thebasiles777 Jul 11, 2016 11:11 AM
    snogreen snogreen Jul 11, 2016 11:43 AM Flag

    I have an alternative view. It wasn't long ago when we woudl see 30%, 40%, 50% even 70% of our daily volume being reported as short trades on FINRA.. But almost immediate;y AFTER teh trial results came out (top the muddy negative)....outr trading volume disappeared soon after some time.and the short trades are NON existent...our trading volume borders almost zero....or even at 30,000 shares - is equal to a mere $12,000. And now ypu see a SIX cent spread between bid and ask? That is reflective that the marketr makers aren't interested in playing. THAT IS A GOOD THING! because they RARELY play teh LONG side....they play short. Whe the MM is NOT shorting that is good!

    I don't know who has hurt us (and TB 4) more....the constant MM shorting over last 10 years......or finkelstein. I suppose finkelstein has hurt us more.

  • Reply to

    Market Cap down to $40 million

    by brewerdfw Jul 8, 2016 9:50 AM
    snogreen snogreen Jul 8, 2016 1:50 PM Flag

    I would not expect any large effect of pressure, because we don't know if TB 4 will do that.byut also, teh pressure was measured JUST AFTER the torture CAE chamber.which is totally sealed and changed of climate. I woudl rather have seen a Day 28 measure, with NO torture chamber. So even a SLIGHT drop in ocular pressure AFTER the torture chamber, COUDl be significant for a trial with NO CAE.and a longer dosing to 40-45 days. All we need is a bint of a pressure drop, and it will be worth doing a small phase 2. won't cost that much. Patienst are everywhere and far easier than EYE NK.....and ORA is all set to do it.

    NEVER understimate the ability of Finkel to do the wrong things. But G Tree does control data.

  • Reply to

    Market Cap down to $40 million

    by brewerdfw Jul 8, 2016 9:50 AM
    snogreen snogreen Jul 8, 2016 12:43 PM Flag

    I do not think G Tree has any spare money to buy more RGRX stock. recall that G Tree had teh right to exercise a handful of million warrants, I think aroudn 15 cents...a while back, after their 19 million share buy....and they did not take them.

    G Tree did one expensive dry eye with Ora, they now are planning a larger Phase 3. They are slo paying for teh EYE NK trial.cost smay be low, but ORA charges premium prices.

    I am still waiting on final trial data. Where is t? I want to see OSDI.and I REALLy want to see the glaucoma pressure measures that were SNUCK in and NO investors, but us know of.. Because this was a PHASE 2 trial....306 patients, so for all intents throwing that glacoma measure in, in a blinded and placebo controlled trial by ORA...is a sideways Phase 2a trial. If there ever was any drop in intraocular pressure measures in the TB 4 arm.....RGRX woudl be $2 or higher immediately. There was a big flop in a glaucome trial last week....by another tiny pharma.stock collapsed.

  • Reply to

    Dry Eye Bottom Line Results

    by brewerdfw Jul 7, 2016 10:30 AM
    snogreen snogreen Jul 7, 2016 10:35 AM Flag

    He could care less. He got his dilutioon money, as I expected. he has his salary. And he recently issued himself 125,000 FREE stock options.which means basically he had no dilution himself. he never pays for stock....we do.

  • POOF! there goes any hope of Sabby Wabby being able to trade out of the 34 cent stock PIPE deal.....10k shares and we are at 35 cents. I doubt Sabby is dumb enough now to sell stock below his 34 cents cost, so basically he is along for the ride now.

  • snogreen by snogreen Jul 6, 2016 9:34 PM Flag

    You really don't get it. MAny of us here a decade or longer. YES WE TRASH MANAGEMENT, because they deserve to be trashed! Harvard B Scholl shoudl do cse studies on Finkelstein and ho wto screw uo almsot everty time.. what you do NOt get is this.I am perfectly FINE trashing RHRX mgmt, because they seserve to be. In MY mind, not yours, that shows a certain level of intelligence and DD....because HOW MANY OTHER tiny OTC speculative biotechs have NOTHINg but "fan boys" and PUMPERS. Reason why YOU are so upset is because many of us ARE NOT PUMPERS! We tell it like iT IS! We ALL own a #$%$ load of RGRX BECAUSE WE BELIEVE IN TB 4! WE DO NOT BELIEVE FINKESTEIN IS CAPABLE OF ANYTHING!!!....except collecting his salary and TONS of free diluting stock options..

    Walk a MILE in our shoes buddy boy.....SEVERAL MILLION SHARES \are owned by the "mean nasty" posters here you read here. HO MUCH DO YOU OWN? I am personally up to close to several hundred thousand shares. When you can admit to owning that much, then you can moan and groan. Until then? We earned it. We DO NOT "hype to the moon". We TRASjH rgx mgmt VERY RIGHTLY SO!, we are UPBEAT on the prospects of TB 4. THAT is what you miss. RGRX has horrible, horrible, horrible mgmt. TB 4 has always been extremely interesting...if ONLy ift was in teh right hands. Well, I gues it is in G Tree.

  • Reply to

    .40 down .065

    by thebasiles777 Jul 6, 2016 2:43 PM
    snogreen snogreen Jul 6, 2016 3:34 PM Flag

    Don't know what Sabby does. I don't trust them....but then again, NO WAY can they get out of a 5 million PIPE stock buy in RGRX for anywhere close to break even 34 cents. A mere 40k shrs dropped RGRX to 39 cents. Another 100k would get RGRX to 35 cents. So why would Sabby do that? If they try to sell just 250k of 5 million... shares, RGRX is at or below 34 cents. So for little money they screw themselves, mark wise. But who knows. They coudl be using a 3rd party to illegally sell short for them. PIPE investors aren't the classiest people in world....they are bottom feeders.

  • Reply to

    Volume

    by ardentmarr Jul 6, 2016 11:31 AM
    snogreen snogreen Jul 6, 2016 1:50 PM Flag

    walk a mile in our shoes before pontificating. I coudl pick three of the grumpy posters here, you diss..and we'd own over one million shares I bet. I could add just one other, and a couple of his friends.and I bet we'd all own probably 3-4 million shares total.

    We've earned heh right to b****h......you are just a newbie latecomer.

  • Corn and soybean meal.....perhaps the biggest feed costs for raising hogs....are collapsing again today....big. The acerage planted was bigger than expected and weather conditions are good. Corn is cdwon to $3.35 a bushel.....this is a HUGE boon to SEB. but what does SEB do? Go down and down. Tyson, Pilgrims, Sandersons Farns and Hormel are all rallying big time....some to new highs...because te market sees the collapse in grain prices..

    I just don't get it. China pork production is no in a deficit, they are massively incressing USA imports....grains collapse, Hog prices up 40% in about 8 months. the shorts SLAMMED SEB because of low poek prices and higher grain costs. BUT? Hogs INCREASE by 40% and grains DECREASE by 40%...and shorts still slam SEB.

    I do not understand what Bresky is doing. he sits on $500 millioj of CASh and ST investments. he earns no monety on that stuff. His shares have collapsed. All other protein stocks are soaring. SEB earnings will be better gong forward. SEB still collapses. BUY BACK STOCK HERE!

  • This is crazy. SEB is dirt cheap. Hog prices have risen almost 40% from earlier in 2015 lows. China is in shortage of pork and their imports of US pork is increasing rapidly. A few months ago Corn hit almost $4.40 a bushel.corn collapsed....today it is down almost 6% to $3.35 a bushel. then, Soybean meal has also collapsed. SEB's biggest cost is FEED!!! what does SEB do? Go way down. Makes no sense. Corn collapses to 3.35 bushel.soybean meal collapse.....hogs increase almsot 40% in price.and pork deman from China is going way up. every one of those is GREAT for SEB.....Tyson, Pligrims pride.....Sanderson farms....ALL have skyrockted to new highs almost. what does SEB do? go straight down.

    the shorts in SEB are very active.

    I'm looking for a surprisingly strong Q2....but hope that the commodity divison doesn't mess up.

    SEB will also collect $8 million in Q2 from teh 10% interest re set of the $165 million butterball loan. SEB is taking bio fuel tax credits each Q now......and bio fuel prices (which SEB makes) are up strongly.

    Still , SEB all butcollapses? Steve Bresky ought to have his head examined for not buying back tons of shares down here. SEB sits on about $500 MILLION of cash.....after all debt.

  • Reply to

    G Tree up 7.74%

    by snogreen Jul 4, 2016 8:43 AM
    snogreen snogreen Jul 5, 2016 6:47 AM Flag

    EB, EB, EB, EB......think back boi & trot. I'm right. Oue EB trial, whoch was also given FDA Orphan Status.was setroyd by the FDA. Just like they are severly hampering our EYE NK trial.....and teh eye NK has good chance s success, because it is a longer dose and there is no CAE involved.

    The EB found i near impossible to find patients. No parent wantd a plancebo risk....to painful. Same is happening with Eye NK....patients don't want a placebo risk. Finally? After over 6 years, RGRX halted the EB trial because they coudl not get enough patients. I think they had barely a couple dozen. Resultys very muddied.. But dr. Jo-David Fine reported one of his pts showed remarkable healing and never had had any in 20 years..

    EYe NK is our fatest possible approval venue. Only 46 pts and FDA gives expedited 6 month priority review (if it works). So yeah.... Gtree whoudl be talking to FDA about teh trial design.....because alonmg with RGRX , they can say look what the FDA mandates did to that trial. It was finished before it even started.

  • Reply to

    G Tree up 7.74%

    by snogreen Jul 4, 2016 8:43 AM
    snogreen snogreen Jul 4, 2016 4:36 PM Flag

    A few days ago, the Wall Street Journal dia blistering editorial against teh FDA. It was regarding that rare boy's disease and drug approval.. It all goes back to very rare doseasses and PLACEBO. No one wants to take placebo in rare diseases.they want active drug. So this boys disease has some 'statistical" that the FDA did not care for.but on other hand, many boys DID respond to the drug. So what does FDA do? decision is soon? The WSJ has nailed the FDA as often as they can on this IDIOCY at the FDA. the drug worked for many boys, it is safe.so APPORVE IT.

    I've harped on this too. I think eye NK has a real good chance. NO CAE MACHINE!!!!! But the stupid FDA demands placebo. Thus no patients ign up. Maybe the FDA reads the WSJ editorial and will wake up obn rare diseases. I've posted often that G Tree shoudl bring this up at teh FDA summer meeting. The FDA also screwed RGRX before with teh SAME situation in EB trial.6 years and no patients signed up really. but some early look on one pt showed remarkable success. If FDA approves Sarepta.then G Tree can ask to change EYE NK trial

  • snogreen by snogreen Jul 4, 2016 8:43 AM Flag

    G Tree had a nice Monday....up 1,350....7.74%.....closed at the high print of the day......345,000 traded.

  • Well, Finkel picked them yet again.not quiite as bad as a PIPE deal, but not far off it. Sabby is a real penny stock player, and they have been in trouble with the SEC before. but the BAD news is just how their firm is described:

    "Sabby Capital is an activist investment firm that predominantly invests in warrants of small cap healthcare companies."

    Sabby also touts their 'VOLATILITY" fund. read this again:
    "....investment firm that predominantly invests in warrants of small cap healthcare companies."

    So what does that point to" It sure reads to me like they buy a ton of stock, deeply discounted.then they try to trade OUT of teh stock over time, from that low discountd price and try to make a profit off that. but then if they can do that....even for a breal een or small profit.what teh VOLATILTY fund they hype is then left holdimng millions of warrants in tons of companies.....and the warrants are free and they traded out of some stock. A home run if just some of them ever "hit".

    Once again, Finkel dug to the bottom of the barrel.The real #$%$ suckers. he took the easy way out.

    I also noticed that MAXIM charged RGRX an 8% fee...8% is a lot. but then, true to form? RGRX ut MAXIM in for an ALSO over 250,00 FREE warrants.

    RGRX is dealing, again, with teh low lifes of investment world. Sad, but so typical.

  • Reply to

    Are we just a feeder company

    by thebasiles777 Jun 30, 2016 9:29 AM
    snogreen snogreen Jun 30, 2016 1:41 PM Flag

    Hey, I ain't thrilled they used the CAE again....when AGN and Shire refused to (if Ora was working with them). But nothing we can do. but we always KNEW that even IF the trial went swimmingly well, since it was a PHASE 2b/3.another trial woudl have to be done REGARDLESS! So we are just doing another trial, as planned.....the bad issue was that the data looked worse because of CAE, which lowered our share price and forced more dilution from penny sales and warrants.. It coudl have been worse, if they did MORE than $1.75 million.

    the gist of my post on EYE NK is that we KNOW G Tree has a summer meeting w/ FDA....when? At that meeting RGRX/GTree must tell FDA that they cannot get a mere 46 pts for Orphan EYE NK if they face risk of damaging their eyes because they get on a do nothing placebo. I'm not sure I woudl take that 50% chance if I had bad EYE NK issues.....I woudl take whatever to stabilize it and wait for some other sucker to do the placebo in trial.

  • Reply to

    Are we just a feeder company

    by thebasiles777 Jun 30, 2016 9:29 AM
    snogreen snogreen Jun 30, 2016 10:24 AM Flag

    You are missing something. Revenues coudl come far sooner that 2018, IF.....the Phase 3 Orphan Status EYE NK trial gets finished. It is a marketing approval trial. It only has 46 patients needed. With orphan Status, we get an expedited FDA approval review of 6 months....thgere is no good current therapy. the ISSUE is that they have hard time getting patients, because teh Eye NK disease is serious to their vision already....so pts don't want to sign on with a 50% chance of getting a "do nothing" placebo. G Tree needs to ask....no, beg....the FDA to make that trial an open label one.....TB 4 pts only. You will still find out if it works, by simply looking at the eye healing (if any), where no other therapy is that good. you don't need a placebo! if the FDA would loosen that restriction, I bet they coudl sign up 46 patients within a couple months......be DONE in a few months after....and final analysis of only 46 pts goes very quickly. If that trial ever worked, RGRX will skyrocket.....the revenues woudl be on small side, but more importantly it shows TB 4 WORKS....which will increase chances in the final GOOD DESIGNED dry eye final phase 3. if the FDA would loosen the placebo demands, EYE NK coudl be finished and reported within 8 months or so. No need to wait till 2018.

  • snogreen snogreen Jun 28, 2016 12:55 PM Flag

    No big deal that there is size offered at .60..CDEL isn't a long seller.they would offer 60,000 at .60 cents to go short, if anyone wanted it.....and soon they'd buy it back cheaper.

    our bad dilution news is out. the only possible news I see now is what will happen at the "this summer" FDA meeting. WHEN is it? Will the FDA approve Phase 3 final trial design at that meeting? What was OSDI ? Did ANYTHING happen with the glaucoma measures? Will G Tree ask to amend the EYE NK phase 3 to make it an open label trial.since it is pretty apparent they cannot get ill patients to sign up and have 50% of a "do nothing" placebo. if ALL patients were getting active TB 4....I bet they woudl get 46 patients within a month or two.

  • Reply to

    level II early spread

    by thebasiles777 Jun 28, 2016 8:06 AM
    snogreen snogreen Jun 28, 2016 8:39 AM Flag

    1. Be glad it was only $1.75 million and not double that....20 million possible sharess, for $3.5 million, massive dilution, instead of what we got in manageable dilution..

    2. we still own all heart and neuro.

    3. we still own all europe eye rights.

    Now we are in for all or none.We have enough money to pay Finkel and his rent for about a year or more. By that time the last, well done phase 3 will be finished. It is now in G Tree and FDA hands, which is why (WHEN) this "summer FDA meeting" is crucial. we need the same EASY phs 3 design that Shire and AGN got....we need to ask FDA to adjust the EYE NK trial to OPEN LABEL....n o placebo. there is no therapy for EYE NK, so why does a placebo make any sense? then we NEED RGRX to disclose the OSDI measures from trial and we need to see what, if any, effect was seen on glaucoma measures. RGRX is still not disclosing TONS to us.

OB
14.26+0.03(+0.21%)Jul 22 4:02 PMEDT